Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3243
Pancreatic Cancer Market is estimated to register a CAGR of 10.2% during the forecast period 2022 to 2028. In pancreatic cancer, cancerous cells form in the pancreas. Typically, pancreatic cancer begins in the tissues of your pancreas, which lies behind the lower part of your stomach in your abdomen. In addition to releasing enzymes that aid digestion, your pancreas also produces hormones that help you manage your blood glucose levels. It is possible to develop cancerous or noncancerous tumors in the pancreas. Most pancreatic cancers develop in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). There is a high incidence of pancreatic cancer being detected in its early stages when it is most treatable. Because it often doesn't cause symptoms until other organs have been affected, it is difficult to diagnose. In order to treat pancreatic cancer, treatment options are determined by the extent of the disease. The treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these methods. There is a strong link between alcohol consumption and pancreatic cancer. As a result of a fast-paced lifestyle with little time for decongestion and reconnecting with family, the consumption of supportive substances like these two will rise around the world, and pancreatic cancer incidence will rise as well. The risk for this type of cancer increases with diabetes as well. It is now possible to deal with diabetes complications and end results, including pancreatic cancer, thanks to improved healthcare standards. A better surgical technique and more effective chemotherapeutic agents are available today to treat pancreatic cancer. Technological advancements in the field of therapeutics, burgeoning incidences of cancer are some key factors that drive the growth of the market. FutureWise Market Research has instantiated a report that provides an intricate analysis of Pancreatic Cancer Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Pancreatic Cancer Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Pancreatic Cancer Market: • OncoGenex Pharmaceuticals Inc. (U.S.) • Pharmacyte Biotech Inc. (U.S.) • Diffusion Pharmaceuticals (U.S.) • Oncolytics Biotech (Canada) • Sun BioPharma, Inc. (U.S.) • Polaris Pharmaceuticals, Inc. (U.S.) • Clovis Oncology (U.S.) • Eli Lilly and Company (U.S.) • Midatech Pharma PLC (U.K.) • F. Hoffmann-La Roche AG (Switzerland) • Celgene Corporation (U.S.) • Novartis International AG (U.S.) • Amgen, Inc. (U.S.) • Teva Pharmaceutical Industries Ltd • Pfizer, Inc (Note: The list of the major players will be updated with the latest market scenario and trends) Pancreatic Cancer Market Segmentation: By Treatment Biologic Therapy Hormone Therapy Chemotherapy Targeted Therapy Surgery Radiation Therapy Other Treatments By Type Exocrine Pancreas Cancer Endocrine Pancreas Cancer Others By End User Research Institute Hospitals and Clinics Other End Users By Region North America Europe Asia-Pacific Latin America Middle East and Africa Pancreatic Cancer Market Sample Video: Competitive Landscape: Tier 1 players- established companies in the market with a major market share Tier 2 players Emerging players which are growing rapidly New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the Pancreatic Cancer Market By Treatment, By Type, By End User and By Region. To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
In pancreatic cancer, cancerous cells form in the pancreas. Typically, pancreatic cancer begins in the tissues of your pancreas, which lies behind the lower part of your stomach in your abdomen. In addition to releasing enzymes that aid digestion, your pancreas also produces hormones that help you manage your blood glucose levels. It is possible to develop cancerous or noncancerous tumors in the pancreas. Most pancreatic cancers develop in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). There is a high incidence of pancreatic cancer being detected in its early stages when it is most treatable. Because it often doesn't cause symptoms until other organs have been affected, it is difficult to diagnose. In order to treat pancreatic cancer, treatment options are determined by the extent of the disease. The treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these methods. There is a strong link between alcohol consumption and pancreatic cancer. As a result of a fast-paced lifestyle with little time for decongestion and reconnecting with family, the consumption of supportive substances like these two will rise around the world, and pancreatic cancer incidence will rise as well. The risk for this type of cancer increases with diabetes as well. It is now possible to deal with diabetes complications and end results, including pancreatic cancer, thanks to improved healthcare standards. A better surgical technique and more effective chemotherapeutic agents are available today to treat pancreatic cancer.
Technological advancements in the field of therapeutics, burgeoning incidences of cancer are some key factors that drive the growth of the market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Pancreatic Cancer Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Pancreatic Cancer Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Pancreatic Cancer Market: • OncoGenex Pharmaceuticals Inc. (U.S.) • Pharmacyte Biotech Inc. (U.S.) • Diffusion Pharmaceuticals (U.S.) • Oncolytics Biotech (Canada) • Sun BioPharma, Inc. (U.S.) • Polaris Pharmaceuticals, Inc. (U.S.) • Clovis Oncology (U.S.) • Eli Lilly and Company (U.S.) • Midatech Pharma PLC (U.K.) • F. Hoffmann-La Roche AG (Switzerland) • Celgene Corporation (U.S.) • Novartis International AG (U.S.) • Amgen, Inc. (U.S.) • Teva Pharmaceutical Industries Ltd • Pfizer, Inc
(Note: The list of the major players will be updated with the latest market scenario and trends)
Pancreatic Cancer Market Segmentation:
By Treatment
By Type
By End User
By Region
Pancreatic Cancer Market Sample Video:
Competitive Landscape:
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Pancreatic Cancer Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Pancreatic Cancer Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Pancreatic Cancer Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Pancreatic Cancer Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Biologic Therapy 7.2. Hormone Therapy 7.3. Chemotherapy 7.4. Targeted Therapy 7.5. Surgery 7.6. Radiation Therapy 7.7. Other Treatments 8. Pancreatic Cancer Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Exocrine Pancreas Cancer 8.2. Endocrine Pancreas Cancer 8.3. Others 9. Pancreatic Cancer Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Research Institute 9.2. Hospitals and Clinics 9.3. Other End Users 10. North America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. OncoGenex Pharmaceuticals Inc. (U.S.) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Pharmacyte Biotech Inc. (U.S.) 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Diffusion Pharmaceuticals (U.S.) 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Oncolytics Biotech (Canada) 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Sun BioPharma, Inc. (U.S.) 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Polaris Pharmaceuticals, Inc. (U.S.) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Clovis Oncology (U.S.) 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Eli Lilly and Company (U.S.) 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Midatech Pharma PLC (U.K.) 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. F. Hoffmann-La Roche AG (Switzerland) 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. Celgene Corporation (U.S.) 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Novartis International AG (U.S.) 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13. Amgen, Inc. (U.S.) 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14. Teva Pharmaceutical Industries Ltd 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 16.15. Pfizer, Inc. 16.15.1. Company Overview 16.15.2. Product Portfolio 16.15.3. SWOT Analysis 16.15.4. Financial Overview 16.15.5. Strategic Overview 17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations 18. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Pancreatic Cancer Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Pancreatic Cancer Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Pancreatic Cancer Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Pancreatic Cancer Market, By Treatment Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Biologic Therapy 7.2. Hormone Therapy 7.3. Chemotherapy 7.4. Targeted Therapy 7.5. Surgery 7.6. Radiation Therapy 7.7. Other Treatments
8. Pancreatic Cancer Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Exocrine Pancreas Cancer 8.2. Endocrine Pancreas Cancer 8.3. Others
9. Pancreatic Cancer Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Research Institute 9.2. Hospitals and Clinics 9.3. Other End Users
10. North America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028
11. Latin America Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028
12. Europe Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028
13. Asia Pacific Pancreatic Cancer Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028
15. Market Share Analysis and Competitive Landscape 15.1. Global Landscape - Key Players, Revenue and Presence 15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 15.3. Global Emerging Companies 15.4. North America - Market Share Analysis and Key Regional Players 15.5. Europe - Market Share Analysis and Key Regional Players 15.6. Asia Pacific - Market Share Analysis and Key Regional Players 15.7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 16.1. OncoGenex Pharmaceuticals Inc. (U.S.) 16.1.1. Company Overview 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2. Pharmacyte Biotech Inc. (U.S.) 16.2.1. Company Overview 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3. Diffusion Pharmaceuticals (U.S.) 16.3.1. Company Overview 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4. Oncolytics Biotech (Canada) 16.4.1. Company Overview 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5. Sun BioPharma, Inc. (U.S.) 16.5.1. Company Overview 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6. Polaris Pharmaceuticals, Inc. (U.S.) 16.6.1. Company Overview 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7. Clovis Oncology (U.S.) 16.7.1. Company Overview 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8. Eli Lilly and Company (U.S.) 16.8.1. Company Overview 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9. Midatech Pharma PLC (U.K.) 16.9.1. Company Overview 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10. F. Hoffmann-La Roche AG (Switzerland) 16.10.1. Company Overview 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11. Celgene Corporation (U.S.) 16.11.1. Company Overview 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 16.12. Novartis International AG (U.S.) 16.12.1. Company Overview 16.12.2. Product Portfolio 16.12.3. SWOT Analysis 16.12.4. Financial Overview 16.12.5. Strategic Overview 16.13. Amgen, Inc. (U.S.) 16.13.1. Company Overview 16.13.2. Product Portfolio 16.13.3. SWOT Analysis 16.13.4. Financial Overview 16.13.5. Strategic Overview 16.14. Teva Pharmaceutical Industries Ltd 16.14.1. Company Overview 16.14.2. Product Portfolio 16.14.3. SWOT Analysis 16.14.4. Financial Overview 16.14.5. Strategic Overview 16.15. Pfizer, Inc. 16.15.1. Company Overview 16.15.2. Product Portfolio 16.15.3. SWOT Analysis 16.15.4. Financial Overview 16.15.5. Strategic Overview
17. Pre and Post COVID-19 Impact 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the regulations initiated by healthcare administrations 17.5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics